Commentary

Ethical and legal issues in mitochondrial transfer

Ainsley J Newson¹, Stephen Wilkinson² & Anthony Wrigley³

The US National Academies of Science, Engineering and Medicine recently provided conditional endorsement for mitochondrial transfer. While its approach is more conservative in some respects than that of the United Kingdom (which passed its own regulations in 2015), it marks a significant policy development for a potentially large implementer of this emerging intervention. In this perspective, we consider some of the ethical and legal aspects of these policy responses.

Ethical and legal issues in mitochondrial transfer

Mitochondrial transfer (MT) techniques are being developed as one method of enabling at-risk couples to avoid having a child with mitochondrial disease (Richardson et al., 2015). These conditions can affect multiple organ systems, are often debilitating and life-shortening and at present cannot be cured.

Two main MT techniques are proposed: maternal spindle transfer (MST) and pronuclear transfer (PNT) (Richardson et al., 2015). MST is undertaken in oocytes and involves removing the spindle from an oocyte with affected mitochondria and inserting it into an enucleated donor oocyte, which then undergoes in vitro fertilisation. PNT involves creating an embryo using the intended parents’ gametes and removing the pronuclei. This is then transferred into an early embryo created using the intended father’s sperm and a donor oocyte and allowed to develop.

MT raises conceptual, ethical and legal issues (Nuffield Council on Bioethics, 2012). As well as the fundamental question of whether it should be allowed at all, these technologies raise more specific questions. Should they be categorised as a germline genetic modification? Should only male embryos be implanted? Do the children created have a right to know who the oocyte donor was? And what legal liabilities would and should ensue? Each of these is discussed below.

What’s in a name?

Nomenclature in relation to emerging biotechnologies often occurs haphazardly, or is bestowed by those who may not be key to its development. This is unfortunate, as the connotations of a particular term may adversely affect subsequent ethical, public and policy debates (Ravitsky et al., 2015).

Interventions to alter mitochondria in embryos are beset by multiple names, most of which have misleading connotations. To date, the MT technologies described above have been termed “mitochondrial donation”, “mitochondrial replacement”, “mitochondrial therapy”, “mitochondrial transfer” and “three-parent IVF”. Here, we use “mitochondrial transfer” as the most accurate and normatively “neutral” term, albeit recognising that this is an imperfect descriptor given some aspects of MT technologies.

Regulatory activity and policy development

The United Kingdom (UK) was the first country actively to regulate MT; passing regulations that came into force on October 31, 2015 (The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 No. 572). The UK regulations allow clinical use of MT under licence. No licence applications have yet been received, although one is expected soon.

An important policy development also occurred in the United States in February 2016 when a specially constituted committee of the National Academies of Science, Engineering and Medicine (NASEM) sanctioned a slightly narrower use of MT than that regulated in the UK. NASEM recommended that “mitochondrial replacement techniques” should be considered for clinical implementation, subject to certain conditions, including that only male embryos should be implanted (NASEM, 2016).

These regulatory developments should also be considered in the light of the distinct approaches to regulation of reproductive technologies in these jurisdictions (Ouellette et al., 2005). The United Kingdom tightly regulates clinics providing assisted reproductive services and novel reproductive technologies. The United States, in contrast, takes a more laissez-faire approach, which some claim is due to certain constitutional rights. This relative lack of regulation may be one reason why the NASEM report provides detailed recommendations as to the clinical implementation of MT.

Genetically modified children? Ethical and legal implications

MT raises ethical and conceptual concerns over whether it is a form of germline gene therapy, and whether children born following MT are genetically modified. Unlike somatic therapies, germline modifications are not usually permitted due to the perceived risks for future generations. In response, we may ask both how MT should

1 Centre for Values, Ethics and the Law in Medicine, School of Public Health, University of Sydney, Sydney, NSW, Australia. E-mail: ainsley.newson@sydney.edu.au
2 Department of Politics, Philosophy and Religion, Lancaster University, Lancaster, UK
3 Centre for Professional Ethics, School of Law, Keele University, Keele, UK
DOI 10.15252/emmm.201606281 | Published online 21 April 2016

© 2016 The Authors. Published under the terms of the CC BY 4.0 license

EMBO Molecular Medicine Vol 8 | No 6 | 2016 589
be classified and whether modifying the germline is always wrong.

There is as yet no consensus as to whether MT is a genetic modification or germline gene therapy, although key distinctions have been emphasised. First, germline therapies usually target nuclear DNA, whereas MT targets whole mitochondria outside the nucleus. Second, the transplanted mitochondria will only beheritable matrilineally and therefore will not be passed onto male offspring. This can be termed the “quasi-heritability” of MT.

This lack of agreement over MT’s status can also be observed in policy. Both UK policymakers and the NASEM report accept that MT technology is a form of heritable modification. But while key UK policy reports accept that MT has germline implications, they reject MT as a “genetic modification”—a unique policy turn—on the grounds that their working definition of what constitutes a “genetic modification” involves the heritable modification of only nuclear DNA (Public Health Directorate, 2014).

The NASEM report, in contrast, distinguishes between “genetic modification” and “germline modification” (NASEM, 2016, sect 3). NASEM considers genetic modification to be “changes to the genetic material within a cell” and germline modification to be “human inheritable genetic modification”. This distinction allows them to claim that: “MRT [MT] involves genetic modification, but that it constitutes...germline modification...only if used to produce female offspring” (NASEM, 2016, sect 3, p. 8).

Whether MT is a form of genetic modification depends both on how we define “genetic modification” and on the attributes of the specific MT technology employed. While MT would constitute a form of genetic modification under almost every current definition, whether it can always be classified as a germline gene therapy or whether it is classifiable as some other form of intervention is both a matter of recent debate and something that may have subsequent ethical implications for its use (Wrigley et al., 2015).

Sex selection

One notable point of divergence between the British and American policy approaches is that while the NASEM Report recommends “restricting initial first-in-human clinical investigations to male embryos” (NASEM, 2016, sect 4, p. 6), the UK has rejected such an approach.

NASEM’s main argument for this restriction is that, because mitochondrial inheritance is matrilineal, using only male embryos stops MT from being a “germline” genetic modification with its attendant (but theoretical) risks to future generations. The UK Human Fertilisation and Embryology Authority (HFEA), however, argued against a “male embryos only” policy on the grounds that “using sex selection after mitochondrial replacement would expose the embryos to additional intervention”, which might generate extra risk (HFEA, 2013, s.6.19). The UK Government also accepted the safety of all MT, regardless of the biological sex of the children who may be born.

The difference between NASEM and HFEA is therefore less about the ethics of sex selection per se than about weighing different kinds of risk. The HFEA has chosen to prioritise avoiding perceived short-term risks to the first generation of children created (citing concerns about the extra biopsy needed for sex selection), whereas NASEM places greater emphasis on what it sees as longer-term risks to the “gene pool”.

Another risk that should be accounted for is the role of mitochondrial DNA (mtDNA) in “regular” gamete donation. Rendering donation anonymous could therefore be said to undervalue this contribution.

Donor anonymity

Many jurisdictions give the genetic offspring of egg and sperm donors a right to identifying information about those donors. MT then raises the question of whether children born from its use should have similar rights. This has sometimes been couched in terms of whether egg donors for MT are more like “regular” gamete donors, or blood or organ donors. The HFEA, for example, has advised that “mitochondria donors should have a similar status to that of tissue donors” (HFEA, 2013, s.6.64).

Some of the supposed differences between mitochondrial egg donors and “regular” egg donors—which may justify not giving MT-conceived children a right to know—are as follows. First, in “regular” gamete donation, the offspring are quite likely to resemble the donor in noticeable ways; this is not the case for mitochondrial transfer. Second, nuclear DNA is said to be constitutive of a person’s genetic identity in ways that mitochondrial DNA (mtDNA) is not. In addition, “the child’s sense of self would be inherited from their [social] parents” (HFEA, 2013, s.6.49).

Legal risks?

While a comprehensive comparison of global legal regulation for MT is beyond the scope of this article, determining sound legal responses to MT and its possible harms remain live issues.

MT’s potential risks may cause us to wonder about any liability for those who provide it. There are, for example, ongoing tensions in the literature around interactions between mitochondrial and nuclear DNA, and “contamination” by residual mitochondria (Hamilton, 2015).

If (and it is a “big if”) these risks transpire, might this lead to claims for compensation against those providing the technology? Could a child born with suboptimal health as a result of MT successfully bring an action against those who provided the treatment? The answer, in many jurisdictions, is “unlikely” for three main reasons.
First, in countries with common law legal systems, most claims like this—so-called wrongful life claims—tend to fail because of difficulties in making the particular circumstances fit the elements of a cause of action in negligence. This includes the need for the person to show that they have been so badly harmed that they would be better off not having been born. The standard of care for MT is not yet established, as it is experimental. An action in negligence has little to do with a particular jurisdiction’s regulatory approach; rather, it involves (amongst other things) comparing the delivery of a treatment against an established standard.

Second, some types of MT might actually lead to a different person being born altogether; such that no harm is done to a particular person (Wrigley et al, 2015). This issue arises from philosophical reflection upon the nature of harms and wrongful life claims. For an individual to claim to have been harmed by coming into existence, they would have to show that they were worse off as a result of MT. But with some MT techniques, the intervention happens prior to fertilisation. If MT had not taken place, an entirely different person would have been born. Thus, the child claiming harm from MT would have to show that they were worse off as a result of MT and similar questions are already being asked about other developments in human reproduction, such as in vitro generated (“artificial”) gametes and uterus transplants (Newson & Smajdor, 2005; Catsanos et al, 2013; Wilkinson & Williams, 2015). Our ethical and regulatory responses to emerging reproductive technologies need to deal with a wider range of issues than ever before.

Acknowledgements
Professor Stephen Wilkinson’s research is supported by a Wellcome Trust Senior Investigator Award (097897/Z/11/Z).

Conflict of interest
The authors declare that they have no conflict of interest.

References
Catsanos R, Rogers W, Lotz M (2013) The ethics of uterus transplantation. Bioethics 27: 65 – 73
Haimes E, Taylor K (2015) Rendered invisible? The absent presence of egg providers in UK debates on the acceptability of research and therapy for mitochondrial disease. Monash Bioeth Rev 33: 360 – 378
Hamilton G (2015) The mitochondria mystery. Nature 525: 444 – 446
Human Fertilisation and Embryology Authority (HFEA) (2013) Mitochondrial Replacement Consultation: advice for Government. London: HFEA
National Academies of Sciences Engineering and Medicine (NASEM) (2016) Mitochondrial Replacement Techniques: ethical, Social, and Policy Considerations. Washington DC: The National Academies Press
Newson AJ, Smajdor AC (2005) Artificial gametes: new paths to parenthood? J Med Ethics 31: 184 – 186
Nuffield Council on Bioethics (2012) Novel Techniques for the Prevention of Mitochondrial DNA Disorders: an Ethical Review. London: Nuffield Council on Bioethics
Ouellette A, Caplan A, Carroll K, Fossett JW, Bjanadottir D, Shickle D, McGee G (2005) Lessons across the pond: assisted reproductive technology in the United Kingdom and the United States. Am J Law Med 31: 419 – 446
Public Health Directorate/Health Science and Bioethics Division (2014) Mitochondrial Donation: Government Response to the Consultation on Draft Regulations to Permit the Use of New Treatment Techniques to Prevent the Transmission of a Serious Mitochondrial Disease from Mother to Child. London: Department of Health
Ravitsky V, Birko S, Dupras-Leduc R (2015) The “three-parent baby”: a case study of how language frames the ethical debate regarding an emerging technology. Am J Bioeth 15: 57 – 60
Richardson J, Irving L, Hyslop LA, Choudhary M, Murdoch A, Turnbull DM, Herbert M (2015) Assisted reproductive technologies to prevent transmission of mitochondrial DNA disease. Stem Cells 33: 639 – 645
Wilkinson S, Williams NJ (2015) Should uterus transplants be publicly funded? J Med Ethics doi:10.1136/medethics-2015-102999
Wrigley A, Wilkinson S, Appleby JB (2015) Mitochondrial replacement: ethics and identity. Bioethics 29: 631 – 638

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.